Proceedings book download - 5Z.com

Table 2. Results of evaluation of radical scavenging activity of hydroxycinnamoylamides( % ) RSA0.9 mM 1.8 mM 3.6 mMReaction time ( min )AH 10' 20' 10' 20' 10' 20'Caffeic acid (Caf А) 23.8 ± 0.4 24.01 ± 0.04 35.9 ± 0.9 38.9 ± 4.5 79.3 ± 2.3 83.9 ± 3.9(1) Caf А-phenylethylamine 41.85±1.55 44.29±1.55 77.33±2.33 80.37±2.31 93.43±0.09 94.21±0.96(6) CafА - tryptamine 30.72±2.15 33.25±2.50 59.12±2.05 63.13±2.09 90.41±0.37 90.82±0.36(9) CafA -Тrp-OCH 3 27.1 ± 2.1 28.7 ± 2.2 44.6 ± 1.7 50.4 ± 1.7 80.1 ± 8 87.9 ± 0.3Sinapic acid (SA) 16.1 ± 0.5 17.2 ± 0.3 26.5 ± 0.1 31.9 ± 0.1 69.0 ± 1.8 69.6 ± 1.0(7) SA- tryptamine 8.76±0.30 9.90±0.30 16.58±1.22 18.33±1.17 33.67±1.11 39.25±1.03(2) SA- phenylethylamine 11.83±0.89 13.40±0.72 22.00±0.35 24.07±0.10 37.99±3.20 41.06±3.55(10) SA–Trp– OCH 3 8.6 ± 0.7 12.9 ± 0.8 14.0 ± 0.05 15.2 ± 0.8 32.5 ± 0.01 39.5 ± 1.1(4) SA-Phe-OBu t 12.0 ± 0.1 13.2 ± 0.1 20.0 ± 1.6 24.9 ± 0.6 36.8 ± 3.4 40.2 ± 4.9Ferulic acid (FA) 12.0 ± 0.1 13.8 ± 0.3 21.0 ± 0.2 25.1 ± 0.4 36.7 ± 0.1 44.3 ± 0.1(11) FA –Trp– OCH 3 2.5 ± 1.0 4.52 ± 0.05 5.2 ± 0.1 9.9 ± 0.1 6.8 ± 0.7 13.4 ± 0.5(5) FA-Phe-OBu t 7.5 ± 0.2 10.4 ± 0.2 11.4 ± 1.8 17.8 ± 1.3 16.4 ± 1.6 29.3 ± 0.2(8) FA-tryptamine 11.09±1.47 13.68±1.67 20.86±0.30 23.04±0.38 33.12±1.43 37.46±1.61(3) FA-phenylethylamine 11.31±0.33 13.36±0.42 20.34±1.37 23.42±1.46 33.89±1.26 38.85±1.41% RSA—percent radical scavenging activity;% RSA =[(Abs 516nm (t=0) - Abs 516nm(t= t’) ) x 100/Abs 516nm(t=0) ], as proposed by Nenadis et al.[5].The DPPH assay results showed that the type of amino component (aromatic amines ortheir corresponding amino acid precursors) in the 3-phenylpropenoylamides affectedinsignificantly the antioxidative activity. All hydroxycinnamic acid amides ofphenylethylamine were the most potent compounds, especially N-caffeoylphenylethylamine.With the exception of caffeoylamides, all tested hydroxycinnamoylamideshave shown lower RSA than the corresponding free phenolic acid.AcknowledgmentsFor the support of this work we are grateful to the contracts: VUL-304/07 and SRP-C2.References1. Halliwell, B. Biochemical Society Transactions 35, 1147-1150 (2007).2. Sortino, C., Politi, M., Morelli, I., Mendez, J. J. Ethnopharmacol. 79, 379-381 (2002).3. Maxwell, S.R. Drugs 49, 345-361 (1995).4. Aruoma, O.I. JAOCS 75, 199-212 (1998).5. Nenadis, N., Boyle, S., Bakalbassis, E.G., Tsimidou, M. JAOCS 80, 451-458 (2003).57